Pharmaceutical companies
Pharmaceutical industry support
The Leukaemia Foundation is pleased to have long-term and strong working relationships with many pharmaceutical companies which market drugs used in the treatment of leukaemia, lymphoma, myeloma and the related blood disorders.
These companies have provided support to the Leukaemia Foundation through unrestricted educational grants. These grants allow us to:
- facilitate patient, carer and family awareness and understanding of leukaemias, lymphomas and myeloma; and
- increase the Leukaemia Foundation's 'reach' of patients and families living with these diseases
Specifically, support through the unrestricted educational grants has helped us to:
- print patient information booklets
- deliver general and disease-specific education programs across every state and territory
- facilitate patient conferences
- raise awareness of leukaemias, lymphomas and myeloma
Some companies also sponsor our Support Service staff to attend research and medical conferences about haematological cancers to assist in the ongoing professional development of our staff.
Supporting companies
Supporters of the Leukaemia Foundation's activities from the pharmaceutical sector include:
- Roche Products Pty Ltd
- Novartis Pharmaceuticals Australia Pty Ltd
- Amgen Australia Pty Ltd
- Pharmion Pty Ltd
- Janssen-Cilag Pty Ltd
- Schering Pty Ltd and
- Biotech Division of Schering Plough Pty Ltd
We would like to thank these organisations for their ongoing commitment to building awareness about leukaemias, lymphomas, myeloma and related blood disorders as well as to improve the quality of lives of patients and families living with these diseases.
All funding received through pharmaceutical companies' unrestricted educational grants is underpinned by the following principles: honesty, integrity, openness, transparency, accountability and respect for the independence of both parties. The Leukaemia Foundation uses the materials developed by the Consumer Health Forum and Medicines Australia to guide the development of its relationship with individual pharmaceutical companies.
